Prostate cancer: 12. The economic burden.
作者信息
Grover S A, Zowall H, Coupal L, Krahn M D
机构信息
Centre for the Analysis of Cost-Effective Care, Montreal General Hospital, Que.
出版信息
CMAJ. 1999 Mar 9;160(5):685-90.
Abstract
摘要
相似文献
1
Prostate cancer: 12. The economic burden.前列腺癌：12. 经济负担。
CMAJ. 1999 Mar 9;160(5):685-90.
2
3
[The economic burden of prostate cancer. A systematic literature overview of registry-based studies].[前列腺癌的经济负担。基于登记处研究的系统文献综述]
Orv Hetil. 2014 Mar 30;155(13):509-20. doi: 10.1556/OH.2014.29837.
4
The economic burden of prostate cancer.前列腺癌的经济负担。
BJU Int. 2011 Sep;108(6):806-13. doi: 10.1111/j.1464-410X.2011.10365.x.
5
Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.前列腺癌管理中的技术变革导致医疗成本增加——一项针对瑞典特定人群的回顾性研究
Scand J Urol Nephrol. 2003;37(3):226-31. doi: 10.1080/00365590310008109.
6
The economic burden of prostate cancer, California, 1998.1998年加利福尼亚州前列腺癌的经济负担。
Cancer. 2002 Jun 1;94(11):2906-13. doi: 10.1002/cncr.10532.
7
Healthcare costs associated with prostate cancer: estimates from a population-based study.前列腺癌相关的医疗保健费用：基于人群的研究估计。
BJU Int. 2010 Feb;105(3):338-46. doi: 10.1111/j.1464-410X.2009.08758.x. Epub 2009 Jul 7.
8
Methodological considerations in cost of prostate cancer studies: a systematic review.前列腺癌研究成本的方法学考量：一项系统综述
Value Health. 2008 Sep-Oct;11(5):878-85. doi: 10.1111/j.1524-4733.2008.00327.x. Epub 2008 May 20.
9
The dilemma of prostate cancer--a growing human and economic burden irrespective of treatment strategies.前列腺癌的困境——无论治疗策略如何，其对人类和经济的负担都在不断加重。
Acta Oncol. 1997;36(7):681-7. doi: 10.3109/02841869709001337.
10
Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.加拿大局限性和晚期前列腺癌的管理：终生成本与质量调整生命年分析
Cancer. 2016 Apr 1;122(7):1085-96. doi: 10.1002/cncr.29892. Epub 2016 Feb 1.
引用本文的文献
1
The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.转移性激素敏感和非转移性去势抵抗性前列腺癌的卫生经济学：系统文献回顾及其在加拿大背景下的应用。
Curr Oncol. 2022 May 7;29(5):3393-3424. doi: 10.3390/curroncol29050275.
2
Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017.基于2015年至2017年国家医疗保险数据库的中国前列腺癌患者医疗服务利用情况及费用
Front Pharmacol. 2020 Jun 10;11:719. doi: 10.3389/fphar.2020.00719. eCollection 2020.
3
Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer.靶向蛋白质组学鉴定出用于前列腺癌囊外侵犯的液体活检标志物。
Nat Commun. 2016 Jun 28;7:11906. doi: 10.1038/ncomms11906.
4
Cost of illness of the prostate cancer in Japan--a time-trend analysis and future projections.日本前列腺癌的疾病成本——时间趋势分析与未来预测
BMC Health Serv Res. 2015 Oct 5;15:453. doi: 10.1186/s12913-015-1103-x.
5
Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.在美国管理式医疗人群中，接受肿瘤学家和泌尿科医生治疗的去势抵抗性前列腺癌患者的治疗模式存在差异。
Cancer Manag Res. 2011;3:233-45. doi: 10.2147/CMR.S21033. Epub 2011 Jul 4.
6
Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data.法国前列腺癌临床管理的成本研究：基于人群数据的结果。
Eur J Health Econ. 2011 Aug;12(4):363-71. doi: 10.1007/s10198-010-0250-6. Epub 2010 Jun 13.
7
Quality of life and economic considerations in the management of prostate cancer.前列腺癌管理中的生活质量与经济考量
Pharmacoeconomics. 2003;21(8):527-41. doi: 10.2165/00019053-200321080-00001.
8
9
10
本文引用的文献
1
Orchidectomy and hormonal therapy of prostate cancer.前列腺癌的睾丸切除术及激素治疗
Can J Urol. 1995 Jan;2(1):109-15.
2
Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al. (Health Policy, 8(1987) 317-323).疾病成本研究：对决策没有帮助吗？对希尔等人的第二种观点的评论（《卫生政策》，第8卷（1987年），第317 - 323页）
Health Policy. 1989;11(1):57-60. doi: 10.1016/0168-8510(89)90055-9.
3
The state of the art of cost-of-illness estimates.疾病成本估算的技术现状。
Adv Health Econ Health Serv Res. 1983;4:129-64.
4
Cost-of-illness studies: a major headache?疾病成本研究：一大难题？
Pharmacoeconomics. 1992 Jul;2(1):1-4. doi: 10.2165/00019053-199202010-00001.
5
Prostate cancer: 1. The descriptive epidemiology in Canada.前列腺癌：1. 加拿大的描述性流行病学。
CMAJ. 1998 Sep 8;159(5):509-13.
6
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.米托蒽醌联合泼尼松治疗有症状的激素抵抗性前列腺癌的经济学评价：基于一项有姑息治疗终点的加拿大随机试验
J Clin Oncol. 1998 Jun;16(6):2272-9. doi: 10.1200/JCO.1998.16.6.2272.
7
Laboratory survey of prostate specific antigen testing in Ontario.安大略省前列腺特异性抗原检测的实验室调查。
Clin Biochem. 1998 Feb;31(1):47-9. doi: 10.1016/s0009-9120(97)00141-0.
8
Prostate cancer: where are we and where are we going?前列腺癌：我们现在所处的位置以及未来的发展方向？
Br J Urol. 1997 Mar;79 Suppl 1:2-7. doi: 10.1111/j.1464-410x.1997.tb00794.x.
9
Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians.前列腺癌的早期检测。第二部分：评估风险、益处和成本。美国医师学会。
Ann Intern Med. 1997 Mar 15;126(6):468-79. doi: 10.7326/0003-4819-126-6-199703150-00010.
10
Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy.二次诊断病理学的临床及成本影响。根治性前列腺切除术前行前列腺活检的回顾。
Am J Surg Pathol. 1996 Jul;20(7):851-7. doi: 10.1097/00000478-199607000-00008.
Zotero 插件